Biotech firm Ocugen's Q2 revenue beats expectations at $1.37 mln

Reuters

Aug 01

Biotech firm <a href="https://laohu8.com/S/OCGN">Ocugen</a>'s <a href="https://laohu8.com/S/QTWO">Q2</a> revenue beats expectations at $1.37 mln

Overview

Ocugen Q2 revenue beats analyst expectations, reaching $1.37 mln
Company initiates dosing in OCU410ST Phase 2/3 GARDian3 trial
Ocugen announces reverse merger with OrthoCellix to focus on regenerative therapies

Outlook

Ocugen aims for 2026 BLA filings for OCU400 and OCU410ST
Ocugen progressing with OCU410ST Phase 2/3 trial for Stargardt disease
Proposed merger with OrthoCellix to focus on regenerative cell therapies

Result Drivers

CLINICAL TRIAL ADVANCEMENT - Ocugen is actively dosing patients in late-stage trials for OCU400 and OCU410ST
STRATEGIC PARTNERSHIPS - Signed binding term sheet for exclusive Korean rights to OCU400, with potential payments up to $11 mln

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Revenue	Beat	$1.37 mln	$350,000 (4 Analysts)
Q2 EPS		-$0.05
Q2 Net Income		-$14.74 mln
Q2 Operating Expenses		$15.17 mln
Q2 Profit From Operations		-$13.80 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Ocugen Inc is $7.00, about 85.3% above its July 31 closing price of $1.03

Press Release: ID:nGNX403Df3

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2556150288"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556150288\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556150288?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-01 20:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556150288","market":"nz","top_or_hot":-1,"title":"Biotech firm Ocugen's Q2 revenue beats expectations at $1.37 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biotech firm <a href=\"https://laohu8.com/S/OCGN\">Ocugen</a>'s <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue beats expectations at $1.37 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Ocugen Q2 revenue beats analyst expectations, reaching $1.37 mln</p></li><li><p>Company initiates dosing in OCU410ST Phase 2/3 GARDian3 trial</p></li><li><p>Ocugen announces reverse merger with OrthoCellix to focus on regenerative therapies</p></li></ul><p><span>Outlook</span></p><ul><li><p>Ocugen aims for 2026 BLA filings for OCU400 and OCU410ST</p></li><li><p>Ocugen progressing with OCU410ST Phase 2/3 trial for Stargardt disease</p></li><li><p>Proposed merger with OrthoCellix to focus on regenerative cell therapies</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CLINICAL TRIAL ADVANCEMENT - Ocugen is actively dosing patients in late-stage trials for OCU400 and OCU410ST</p></li><li><p>STRATEGIC PARTNERSHIPS - Signed binding term sheet for exclusive Korean rights to OCU400, with potential payments up to $11 mln </p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td><p>Beat</p></td><td><p>$1.37 mln</p></td><td><p>$350,000 (4 Analysts)</p></td></tr><tr><td><p>Q2 EPS</p></td><td></td><td><p>-$0.05</p></td><td></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$14.74 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$15.17 mln</p></td><td></td></tr><tr><td><p>Q2 Profit From Operations</p></td><td></td><td><p>-$13.80 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p><a href=\"https://laohu8.com/S/WSCO\">Wall Street</a>'s median 12-month price target for Ocugen Inc is $7.00, about 85.3% above its July 31 closing price of $1.03</p></li></ul><p>Press Release: <span>ID:nGNX403Df3</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech firm Ocugen's Q2 revenue beats expectations at $1.37 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech firm Ocugen's Q2 revenue beats expectations at $1.37 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-01 20:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biotech firm <a href=\"https://laohu8.com/S/OCGN\">Ocugen</a>'s <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue beats expectations at $1.37 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Ocugen Q2 revenue beats analyst expectations, reaching $1.37 mln</p></li><li><p>Company initiates dosing in OCU410ST Phase 2/3 GARDian3 trial</p></li><li><p>Ocugen announces reverse merger with OrthoCellix to focus on regenerative therapies</p></li></ul><p><span>Outlook</span></p><ul><li><p>Ocugen aims for 2026 BLA filings for OCU400 and OCU410ST</p></li><li><p>Ocugen progressing with OCU410ST Phase 2/3 trial for Stargardt disease</p></li><li><p>Proposed merger with OrthoCellix to focus on regenerative cell therapies</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CLINICAL TRIAL ADVANCEMENT - Ocugen is actively dosing patients in late-stage trials for OCU400 and OCU410ST</p></li><li><p>STRATEGIC PARTNERSHIPS - Signed binding term sheet for exclusive Korean rights to OCU400, with potential payments up to $11 mln </p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td><p>Beat</p></td><td><p>$1.37 mln</p></td><td><p>$350,000 (4 Analysts)</p></td></tr><tr><td><p>Q2 EPS</p></td><td></td><td><p>-$0.05</p></td><td></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$14.74 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$15.17 mln</p></td><td></td></tr><tr><td><p>Q2 Profit From Operations</p></td><td></td><td><p>-$13.80 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p><a href=\"https://laohu8.com/S/WSCO\">Wall Street</a>'s median 12-month price target for Ocugen Inc is $7.00, about 85.3% above its July 31 closing price of $1.03</p></li></ul><p>Press Release: <span>ID:nGNX403Df3</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCGN","symbol_name":"Ocugen","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nPLX886C63:1","article_id":"2556150288","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556150288","pubTimestamp":1754051753,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biotech firm Ocugen's Q2 revenue beats expectations at $1.37 mlnOverviewOcugen Q2 revenue beats analyst expectations, reaching $1.37 mlnCompany initiates dosing in OCU410ST Phase 2/3 GARDian3 trialOcu","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"OCGN":"Ocugen"},"translate_title":"生物技术公司Ocugen第二季度营收137万美元，超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCGN":0.9},"content_text":"Biotech firm Ocugen's Q2 revenue beats expectations at $1.37 mlnOverviewOcugen Q2 revenue beats analyst expectations, reaching $1.37 mlnCompany initiates dosing in OCU410ST Phase 2/3 GARDian3 trialOcugen announces reverse merger with OrthoCellix to focus on regenerative therapiesOutlookOcugen aims for 2026 BLA filings for OCU400 and OCU410STOcugen progressing with OCU410ST Phase 2/3 trial for Stargardt diseaseProposed merger with OrthoCellix to focus on regenerative cell therapiesResult DriversCLINICAL TRIAL ADVANCEMENT - Ocugen is actively dosing patients in late-stage trials for OCU400 and OCU410STSTRATEGIC PARTNERSHIPS - Signed binding term sheet for exclusive Korean rights to OCU400, with potential payments up to $11 mln Key DetailsMetricBeat/MissActualConsensus EstimateQ2 RevenueBeat$1.37 mln$350,000 (4 Analysts)Q2 EPS-$0.05Q2 Net Income-$14.74 mlnQ2 Operating Expenses$15.17 mlnQ2 Profit From Operations-$13.80 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Ocugen Inc is $7.00, about 85.3% above its July 31 closing price of $1.03Press Release: ID:nGNX403Df3(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}